Adenocarcinoma of Lung Clinical Trial
Official title:
A Phase I Trial of Combination Nab-Paclitaxel and Nintedanib or Nab-paclitaxel and Placebo in Relapsed Non-Small Cell Lung Cancer Adenocarcinoma
A PHASE I/II TRIAL OF COMBINATION NAB-PACLITAXEL AND NINTEDANIB OR NAB-PACLITAXEL AND PLACEBO IN RELAPSED NSCLC ADENOCARCINOMA
The study is divided into 2 parts: Part 1 is the Phase Ib portion of the trial and Part 2 is the Phase II portion of the trial. Once the Trial Steering Committee has completed the dose limiting toxicity (DLT) assessment for Part 1 and confirmed RP2D for Part 2, Part 2 enrolment will proceed. The objective(s) for each part are as follows: Part 1: The objective of Part 1 is to evaluate the safety and tolerability of combination nab-paclitaxel and nintedanib in patients with stage IIIb and IV adenocarcinoma of the lung in second and third treatment line setting and to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of nintedanib when given with nab-paclitaxel at 100mg/m2 d1, d8 q21. Part 2: The primary objective of Part 2 is to explore the efficacy of combination nab-paclitaxel and nintedanib versus nab-paclitaxel and placebo in the same patient population, with nintedanib/placebo given at the recommended phase 2 dose (RP2D) as defined during part 1 of the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04122833 -
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
|
||
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT04027946 -
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Not yet recruiting |
NCT05079022 -
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
|
Phase 1/Phase 2 | |
| Completed |
NCT02616211 -
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
|
||
| Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
| Recruiting |
NCT05550961 -
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
|
||
| Active, not recruiting |
NCT05292859 -
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
|
||
| Not yet recruiting |
NCT05565677 -
Prognostic Value of Lung Cancer MicroAnatomy in 3D
|
||
| Completed |
NCT05252676 -
Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)
|
||
| Recruiting |
NCT03838588 -
The Tracking Molecular Evolution for NSCLC (T-MENC) Study
|
||
| Recruiting |
NCT04105270 -
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
|
Phase 2 | |
| Not yet recruiting |
NCT02946216 -
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
|
N/A | |
| Completed |
NCT00073398 -
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04770688 -
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
|
Phase 1/Phase 2 | |
| Completed |
NCT04165759 -
HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008)
|
||
| Completed |
NCT04086680 -
The Detection of EGFR Mutations in Liquid Based Cytology Samples
|
||
| Completed |
NCT01362790 -
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06299163 -
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03298763 -
Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer
|
Phase 1/Phase 2 |